SQUAWK/NEWS
Account
Theme
Account
Menu
Live News EQUITY ARTICLE M impact

Intellia Therapeutics lands non-dilutive OrbiMed debt facility up to $400M

Intellia Therapeutics secured a non-dilutive debt facility with OrbiMed for up to $400 million: $75 million funded upfront and $325 million tied to milestones, aimed at added strategic flexibility.

NTLA

Intellia Therapeutics said it has secured a non-dilutive debt facility from OrbiMed, with $75 million funded upfront and an additional $325 million tied to milestones. The company said the financing is intended to provide strategic flexibility through anticipated value inflection points. CAMBRIDGE, Mass., Sept. 04, 2026 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc.

NASDAQ:NTLA, a leading biopharmaceutical company focused on revo…

Related stories